LQDA

As of 2026-10-26, LQDA scores 48out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. LQDA trades at $43.74, within its fair-value band.

LQDA scores 48 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 48. Its strongest factor is quality at 72 (strong), where earnings quality and balance-sheet strength stand out, followed by value at 62. The weakest is sentiment at 20, where sentiment signals are working against it. Among Healthcare stocks it sits in the lower 43% of Healthcare names by composite.

On valuation, LQDA is priced around the middle of its recent range. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 49. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on LQDA, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where LQDA sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for LQDA runs $27.74–$57.62. Current price $43.74 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.